GARDASIL 9 Rx
Generic Name and Formulations:
9-valent human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, and 58 vaccine; recombinant; aluminum adsorbed, susp for IM inj; preservative-free.
Merck & Co., Inc.
Indications for GARDASIL 9:
In females 9–45yrs old, to prevent cervical, vulvar, vaginal and anal cancer caused by HPV types 16, 18, 31, 33, 45, 52, and 58; genital warts caused by HPV types 6 and 11; cervical intraepithelial neoplasia (CIN) grades 2 and 3 and cervical adenocarcinoma in situ (AIS), cervical intraepithelial neoplasia (CIN) grade 1, vulvar intraepithelial neoplasia (VIN) grades 2 and 3, vaginal intraepithelial neoplasia (VaIN) grades 2 and 3, and anal intraepithelial neoplasia (AIN) grades 1, 2, and 3 caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. In males 9–45yrs old, to prevent anal cancer caused by HPV types 16, 18, 31, 33, 45, 52, and 58; genital warts caused by HPV types 6 and 11; and anal intraepithelial neoplasia (AIN) grades 1, 2, and 3 caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58.
Limitations Of use:
Not a substitute for routine cervical or anal cancer screening. Not for protection against disease from vaccine HPV types through exposure to sexual activity or diseases due to HPV types other than 6, 11, 16, 18, 31, 33, 45, 52, and 58. Not for treating external genital lesions; cervical, vulvar, vaginal, and anal cancers; CIN; VIN; VaIN; or AIN. May not protect all vaccine recipients.
Adults and Children:
Give by IM inj in deltoid or upper thigh. Each dose is 0.5mL. <9yrs: not established. 9–14yrs: 2-dose regimen: give 1st dose at elected date, 2nd dose 6–12mos after the 1st dose (if the 2nd dose is given earlier than 5mos after the 1st dose, administer a 3rd dose at least 4mos after the 2nd dose). Or, 9–45yrs: 3-dose regimen: give 1st dose at elected date, 2nd dose 2mos after the 1st dose, and 3rd dose 6mos after the 1st dose. Monitor patients for 15mins after administration.
Immunosuppressed. Have treatment available to manage anaphylactic reactions. Pregnancy. Nursing mothers.
Immunosuppressants: may get suboptimal response.
Inj site reactions, headache, pyrexia, nausea, dizziness; post-administration syncope (may be associated with tonic-clonic movements and other seizure-like activity).
Register pregnant patients exposed to Gardasil 9 by calling (800) 986-8999.
Single-dose vials—10; Prefilled syringes (w. tip caps)—10
Renal and Urology News Articles
- Kidney Damage in Younger Adults Tied to NSAID Use
- Dialysis and Transplant Patients at Increased Risk for Cancer Death
- Guidelines Updated for Pulmonary Arterial Hypertension in Adults
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Darolutamide Improves Metastasis-Free Survival in CRPC
- Prednisone to Blame for ERA 223 Trial Failure?
- Clinicians Somewhat Favor Shared Decision-Making in Older mCRPC Patients
- Higher Push-Up Capacity Linked to Lower Incidence of CVD Events
- Pembrolizumab Shows Promise for BCG-Unresponsive Bladder Cancer
- Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)